23 companies in this supply chain, sorted by market share.
World's largest insulin manufacturer. Controls ~33.7% of global diabetes care market; ~45% of human insulin. Operates the world's largest insulin production facility in Kalundborg, Denmark (produces ~50% of global insulin supply). Dominant in GLP-1 drugs (Ozempic/Wegovy); FY2024 revenue DKK 232B. Uses both E. coli and yeast fermentation.
Supplies these inputs
GLP-1 Disposable Injection Pen / Auto-Injector · Pen Needles (Subcutaneous Injection) · GLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type)
Replaceability
Substitutability 5% · 60 mo to replace
Business segments
- Insulin (World #1 — ~45% Global Market)30% rev
- GLP-1 Drugs (Ozempic + Wegovy + Victoza)55% rev
- Rare Disease + Hemophilia15% rev
Major medical device company with captive EO sterilization; Sandy Utah facility; at risk of shutdown from EPA regulations (FDA warned against closure); IV catheters and other critical devices
Supplies these inputs
Pen Needles (Subcutaneous Injection)
Business segments
- Medical (Syringes, Needles, IV Catheters)40% rev
- Life Sciences (Flow Cytometry, Genomics)25% rev
- Diagnostics (Caruana, Kiestra)20% rev
- Pharmaceutical Systems15% rev
German pharmaceutical glass specialist (FRA: 1SXP; IPO September 2023 at ~€3.6B market cap); subsidiary of SCHOTT AG, which is wholly owned by the Carl Zeiss Foundation — a non-profit foundation structure that has owned SCHOTT since 1884. SCHOTT Pharma is the world's largest manufacturer of pharmaceutical primary packaging glass, holding an estimated 35-45% of the global pharmaceutical borosilicate glass tubing market from which vials, ampoules, and syringes are drawn. Type I borosilicate glass has been SCHOTT's core product since founder Otto Schott invented borosilicate glass composition in 1884, and SCHOTT has the longest continuous manufacturing history of any pharmaceutical glass maker. Key pharmaceutical glass vial production plants in Müllheim (Germany), Jena (Germany), Schweinfurt (Germany), and multiple international sites. Supplied hundreds of millions of vials for COVID-19 vaccine programs including BioNTech/Pfizer mRNA vaccines.
Supplies these inputs
Ready-to-Use Type I Borosilicate Glass Cartridge (Pen)
Business segments
- Pharmaceutical Glass Tubing (Type I Borosilicate)40% rev
- Formed Packaging (Vials + Syringes + Cartridges)55% rev
- Specialty Containers5% rev
German pharma packaging specialist; ~30–35% global pharma glass packaging alongside Schott; acquired Bormioli Pharma Dec 2024; also produces LDPE ophthalmic dropper bottles (System A).
Supplies these inputs
Ready-to-Use Type I Borosilicate Glass Cartridge (Pen)
Business segments
- Primary Packaging Glass (Vials, Ampoules, Cartridges)40% rev
- Primary Packaging Plastics (Dropper Bottles + COP/COP)30% rev
- Advanced Technologies (Drug Delivery Devices)30% rev
Italian pharmaceutical glass packaging company (NYSE: STVN since June 2021 IPO; family-owned by Stevanato family; ~€800M revenue 2023); headquartered in Piombino Dese, Veneto, Italy. Stevanato is the world's second-largest pharmaceutical glass primary packaging manufacturer and the largest independent vial converter — buying borosilicate glass tubing from SCHOTT and converting it to finished pharmaceutical vials, syringes, and cartridges. Also manufactures the vial-forming machines used in vial conversion (through subsidiary Spami). Stevanato's Piombino Dese campus is one of the highest-capacity pharmaceutical glass vial conversion sites in Europe. Major supplier to COVID-19 vaccine programs. Expanding Fishers, Indiana (US) greenfield glass/plastic hybrid plant (opening 2025) for North American market.
Supplies these inputs
Ready-to-Use Type I Borosilicate Glass Cartridge (Pen)
Business segments
- Biopharmaceutical & Diagnostic Solutions (BDS)75% rev
- Engineering (Spami / Vial-Forming Machines)15% rev
- Drug Delivery Systems (DDS)10% rev
Second-largest insulin manufacturer; invented the first commercial insulin (1923). Uses Saccharomyces cerevisiae (yeast) fermentation exclusively. Markets Humalog (lispro), Basaglar (glargine), and Lyumjev. Also dominant in GLP-1 market (Mounjaro/Zepbound). FY2024 revenue ~$45B.
Supplies these inputs
GLP-1 Disposable Injection Pen / Auto-Injector
Business segments
- Insulin (First Commercial Insulin, 1923)15% rev
- GLP-1 (Mounjaro + Zepbound = Tirzepatide)45% rev
- Oncology (Verzenio + Kisunla)25% rev
- Immunology + Neuroscience15% rev
One of the world's largest peptide & amino-acid makers; 200+ Fmoc unnatural amino-acid SKUs.
Supplies these inputs
SPPS Reagents — Protected Amino Acids, Resins & C18 Fatty-Diacid Side Chain
Replaceability
Substitutability 30% · 18 mo to replace
Business segments
- Protected amino acids (Fmoc / Boc)
- Peptide synthesis reagents & resins
- Custom & contract peptide synthesis (CRO/CDMO)
Swiss self-injection device maker; YpsoMate autoinjector platform. Carved out its diabetes unit to focus on GLP-1 self-injectors and signed a long-term autoinjector supply deal with Novo Nordisk.
Supplies these inputs
GLP-1 Disposable Injection Pen / Auto-Injector · Pen Needles (Subcutaneous Injection)
Replaceability
Substitutability 30% · 30 mo to replace
Business segments
- Delivery Systems73% rev
- Diabetes Care (mylife)27% rev
Japanese diversified medical device and pharmaceutical packaging company (TYO: 8086; ~¥500B revenue); headquartered in Osaka. Nipro is the largest pharmaceutical glass vial manufacturer in Japan and a major global supplier, holding an estimated 10-15% of global pharmaceutical glass vial market share. Nipro's pharma glass operations span borosilicate vial production (Nipro Pharma Corporation subsidiary) and medical device manufacturing. Nipro is one of the few manufacturers with both pharmaceutical glass tubing drawing capability AND vial conversion capacity in-house — a vertical integration comparable to SCHOTT Pharma. Major supplier to Japanese domestic pharmaceutical manufacturers; growing export market in Asia, India, and emerging markets. Also the world's largest manufacturer of hemodialysis equipment and supplies.
Supplies these inputs
Ready-to-Use Type I Borosilicate Glass Cartridge (Pen)
Business segments
- Pharmaceutical Glass (Vials + Syringes)35% rev
- Dialysis Equipment + Supplies (World #1)40% rev
- Medical Devices + CDMO25% rev
Swiss peptide CDMO; largest independent peptide API manufacturer globally; $1B+ expansion at Bubendorf Switzerland; key GLP-1 API supplier for generics and biosimilar programs
Supplies these inputs
GLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type) · SPPS Reagents — Protected Amino Acids, Resins & C18 Fatty-Diacid Side Chain
Replaceability
Substitutability 40% · 18 mo to replace
Business segments
- GLP-1 & Metabolic Peptide APIs45% rev
- Oncology & Specialty Peptide APIs28% rev
- Contract Development & Manufacturing (CDMO)18% rev
- Research & Biochemicals9% rev
Major merchant manufacturer of disposable autoinjectors (Molly platform) for GLP-1 and other self-administered biologics.
Supplies these inputs
GLP-1 Disposable Injection Pen / Auto-Injector
Replaceability
Substitutability 30% · 30 mo to replace
Business segments
- Advanced Drug Delivery Systems (autoinjectors)
- Pen injectors & other self-injection devices
- Vertically integrated manufacturing (in-house)
Japanese medical-device maker; pen needles and injection systems.
Supplies these inputs
Pen Needles (Subcutaneous Injection)
Replaceability
Substitutability 50% · 9 mo to replace
Business segments
- Cardiac and Vascular50% rev
- Medical Care Solutions30% rev
- Blood and Cell Technologies (Terumo BCT)20% rev
Swiss CDMO operating European and US API manufacturing sites; primary lipid partner for Moderna; manufactures SM-102 and full LNP lipid component portfolio including ionizable, PEGylated, phosphocholine, and plant sterols; claims largest complex lipid capacity globally
Supplies these inputs
GLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type) · SPPS Reagents — Protected Amino Acids, Resins & C18 Fatty-Diacid Side Chain
Business segments
- Lipids for LNP mRNA Drug Delivery28% rev
- Therapeutic Peptide APIs (GLP-1, Oncology)25% rev
- Small Molecule APIs (Carbohydrate & Fatty Acid Chemistry)22% rev
- Beta-Lactam Antibiotics & HPAPIs25% rev
Polish OEM maker of pen needles and safety lancets — large contract supplier.
Supplies these inputs
Pen Needles (Subcutaneous Injection)
Replaceability
Substitutability 50% · 9 mo to replace
Business segments
- Pen needles (OEM & branded)
- Safety lancets & blood sampling (OEM)
- Contract device manufacturing
German multinational producing the Hi-Flow Plus nitrocellulose membrane — one of the two industry-standard LFA membranes globally. Received a €121M US DoD/HHS contract to build the first US lateral flow membrane facility in Sheboygan, WI (2022) to reduce concentration risk in Cork, Ireland.
Supplies these inputs
SPPS Reagents — Protected Amino Acids, Resins & C18 Fatty-Diacid Side Chain
Business segments
- Life Science (MilliporeSigma — US Brand)42% rev
- Healthcare (Pharma — Small Relative to Life Science)22% rev
- Electronics / Performance Materials (Liquid Crystals & OLED)28% rev
- Surface Solutions & Specialty Chemicals8% rev
UK medical-device maker; Unifine pen needles and injection devices.
Supplies these inputs
GLP-1 Disposable Injection Pen / Auto-Injector · Pen Needles (Subcutaneous Injection)
Replaceability
Substitutability 30% · 9 mo to replace
Business segments
- Pharmaceutical Services (device CDMO)
- Diabetes & injection (branded)
- Point-of-care & blood sampling
Chinese volume producer of Fmoc-protected amino acids.
Supplies these inputs
SPPS Reagents — Protected Amino Acids, Resins & C18 Fatty-Diacid Side Chain
Replaceability
Substitutability 45% · 9 mo to replace
Business segments
- Protected amino acids (volume production)
- Laboratory & fine chemical reagents
Specialist supplier of Fmoc-protected building blocks, SPPS reagents and peptidomimetics.
Supplies these inputs
SPPS Reagents — Protected Amino Acids, Resins & C18 Fatty-Diacid Side Chain
Replaceability
Substitutability 40% · 12 mo to replace
Business segments
- Protected amino acids & peptide building blocks
- Coupling reagents, resins & linkers
- Peptidomimetics & specialty chemistry
- PEGylation & bioconjugation reagents
